Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

被引：0
|
作者：
O'Brien, Susan M. [1 ]
Jones, Jeffrey A. [2 ]
Furman, Richard R. [3 ]
Coutre, Steven E. [4 ]
Flinn, Ian W. [5 ]
Burger, Jan A. [1 ]
Blum, Kristie A. [2 ]
Sharman, Jeff P. [6 ]
Wierda, William G. [1 ]
Zhao, Weiqiang [2 ]
Heerema, Nyla A. [2 ]
Johnson, Amy J. [2 ]
Tran, Anh [7 ]
Zhou, Cathy [7 ]
Bilotti, Elizabeth [7 ]
James, Danelle F. [7 ]
Byrd, John C. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA
[7] Pharmacyclics Inc, Sunnyvale, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷
关键词：
D O I：
10.1016/j.clml.2015.04.068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
308
引用
收藏
页码：S206 / S206
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of Ibrutinib in Indian patients with chronic lymphocytic leukemia.
    Gogia, Ajay
    Sharma, Atul
    Gupta, Ritu
    Rani, Lata
    Mallick, Saumyaranjan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Long-term follow-up of trisomy 12 by FISH in chronic lymphocytic leukemia.
    Hjalmar, V
    Kimby, E
    Hast, R
    [J]. BLOOD, 2001, 98 (11) : 322A - 323A
  • [43] Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
    Jain, Preetesh
    Thompson, Philip A.
    Keating, Michael
    Estrov, Zeev
    Ferrajoli, Alessandra
    Jain, Nitin
    Kantarjian, Hagop
    Burger, Jan A.
    O'Brien, Susan
    Wierda, William G.
    [J]. CANCER, 2017, 123 (12) : 2268 - 2273
  • [44] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
    Fraser, Graeme
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Goy, Andre
    Avigdor, Abraham
    Rule, Simon
    Phelps, Charles
    Mahler, Michelle
    Salman, Mariya
    Howes, Angela J.
    Balasubramanian, Sriram
    Chanan-Khan, Asher Alban Akmal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
    Fraser, G.
    Cramer, P.
    Demirkan, F.
    Santucci Silva, R.
    Grosicki, S.
    Janssens, A.
    Mayer, J.
    Dilhuydy, M. S.
    Pylypenko, H.
    Loscertales, J.
    Goy, A.
    Avigdor, A.
    Rule, S.
    Phelps, C.
    Mahler, M.
    Salman, M.
    Howes, A.
    Hallek, M.
    [J]. HAEMATOLOGICA, 2016, 101 : 150 - 151
  • [46] Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Analysis of 2083 patients.
    Tsimberidou, Apostolia-Maria
    O'Brien, Susan
    McLaughlin, Peter
    Wen, Sijin
    Wierda, William
    Kantarjian, Hagop M.
    Manning, John
    Lerner, Susan
    Hess, Mark
    Freireich, Emil J.
    Keating, Michael J.
    [J]. BLOOD, 2006, 108 (11) : 790A - 790A
  • [47] Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study
    Burger, J. A.
    Barr, P. M.
    Robak, T.
    Owen, C.
    Ghia, P.
    Tedeschi, A.
    Bairey, O.
    Hillmen, P.
    Coutre, S. E.
    Devereux, S.
    Grosicki, S.
    McCarthy, H.
    Li, J.
    Simpson, D.
    Offner, F.
    Moreno, C.
    Dai, S.
    Dean, J. P.
    James, D. F.
    Kipps, T. P.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 29 - 29
  • [48] Outcomes in high-risk subgroups after fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
    Wierda, William G.
    Jacobs, Ryan
    Barr, Paul M.
    Allan, John N.
    Siddiqi, Tanya
    Tedeschi, Alessandra
    Kipps, Thomas J.
    O'Brien, Susan Mary
    Badoux, Xavier C.
    Visentin, Andrea
    Lasica, Masa
    Carney, Dennis
    Camburn, Anna Elinder
    Torroba, Javier De la Serna
    Szafer-Glusman, Edith
    Zhou, Cathy
    Szoke, Anita
    Dean, James P.
    Ghia, Paolo
    Tam, Constantine S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Coutre, Steven E.
    Furman, Richard R.
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie
    Sharman, Jeff
    Jones, Jeffrey
    Wierda, William
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Tran, Anh
    Zhou, Cathy
    Bilotti, Elizabeth
    James, Danelle F.
    Byrd, John C.
    O'Brien, Susan
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (05) : 1149 - 1155
  • [50] Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies
    Kipps, Thomas J.
    Mahler, Michelle
    Fraser, Graeme
    Coutre, Steven
    Brown, Jennifer
    Barrientos, Jacqueline
    Barr, Paul
    Byrd, John C.
    O'Brien, Susan
    Dilhuydy, Marie Sarah
    Jaeger, Ulrich
    Moreno, Carol
    Cramer, Paula
    Stilgenbauer, Stephan
    Chanan-Khan, Asher
    Salman, Mariya
    Cheng, Mei
    Londhe, Anil
    Ninomoto, Joi
    Howes, Angela
    James, Danelle
    Hallek, Michael
    Hillmen, Peter
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 10 - 12
12345